Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q6)Jun 30, 2025 | (FY)Dec 31, 2024 | (Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | (Q6)Jun 30, 2021 | (FY)Dec 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash flow from operating activities | ||||||||||
| Earning before tax | ---- | 37.13%-13.81M | ---- | 96.46%-21.97M | ---- | -1,022.67%-620.31M | ---- | 45.18%-55.25M | ---- | 84.35%-100.79M |
| Profit adjustment | ||||||||||
| Interest (income) - adjustment | ---- | ---- | ---- | 50.00%-5K | ---- | 28.57%-10K | ---- | 36.36%-14K | ---- | 45.00%-22K |
| Attributable subsidiary (profit) loss | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -40.66%7.07M | ---- | -94.90%11.92M |
| Impairment and provisions: | ---- | ---- | ---- | -100.20%-875K | ---- | 4,054.02%443.61M | ---- | 111.88%10.68M | ---- | -94.12%5.04M |
| -Impairment of property, plant and equipment (reversal) | ---- | ---- | ---- | ---- | ---- | -92.04%510K | ---- | --6.41M | ---- | ---- |
| -Impairmen of inventory (reversal) | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --991K | ---- | ---- |
| -Impairment of trade receivables (reversal) | ---- | ---- | ---- | -100.20%-875K | ---- | --443.1M | ---- | ---- | ---- | ---- |
| -Other impairments and provisions | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -34.96%3.28M | ---- | -94.12%5.04M |
| Asset sale loss (gain): | ---- | ---- | ---- | -99.70%427K | ---- | 4,479.90%143.58M | ---- | 108.44%3.14M | ---- | 125.41%1.5M |
| -Loss (gain) from sale of subsidiary company | ---- | ---- | ---- | -99.70%427K | ---- | 3,604.93%143.57M | ---- | 308.32%3.88M | ---- | --949K |
| -Loss (gain) on sale of property, machinery and equipment | ---- | ---- | ---- | ---- | ---- | 101.89%14K | ---- | -233.33%-740K | ---- | 150.23%555K |
| Depreciation and amortization: | ---- | 0.00%108K | ---- | -77.73%108K | ---- | -88.06%485K | ---- | -66.80%4.06M | ---- | -63.99%12.24M |
| Financial expense | ---- | -79.73%15K | ---- | -51.95%74K | ---- | -48.67%154K | ---- | -64.83%300K | ---- | -50.58%853K |
| Special items | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -99.92%8K | ---- | -95.36%9.68M |
| Operating profit before the change of operating capital | ---- | 38.45%-13.69M | ---- | 31.55%-22.24M | ---- | -8.26%-32.49M | ---- | 49.63%-30.01M | ---- | 43.02%-59.59M |
| Change of operating capital | ||||||||||
| Inventory (increase) decrease | ---- | ---- | ---- | ---- | ---- | -93.54%103K | ---- | -6.73%1.59M | ---- | -78.21%1.71M |
| Accounts payable increase (decrease) | ---- | -2.59%11.5M | ---- | 13.28%11.8M | ---- | 1,347.22%10.42M | ---- | 103.52%720K | ---- | -134.51%-20.47M |
| prepayments (increase)decrease | ---- | -55.43%2.46M | ---- | 11.48%5.52M | ---- | -1.53%4.95M | ---- | 131.24%5.03M | ---- | ---16.09M |
| Cash from business operations | ---- | 105.43%267K | ---- | 71.09%-4.92M | ---- | 24.93%-17.02M | ---- | 75.99%-22.67M | ---- | -205.06%-94.44M |
| Special items of business | -88.24%14K | ---- | 104.52%119K | ---- | 63.69%-2.64M | ---- | 28.55%-7.26M | ---- | 91.82%-10.16M | ---- |
| Net cash from operations | -88.24%14K | 105.43%267K | 104.52%119K | 71.09%-4.92M | 63.69%-2.64M | 24.93%-17.02M | 28.55%-7.26M | 75.99%-22.67M | 91.82%-10.16M | -205.06%-94.44M |
| Cash flow from investment activities | ||||||||||
| Interest received - investment | ---- | ---- | ---- | -50.00%5K | ---- | --10K | ---- | ---- | ---- | -45.00%22K |
| Decrease in deposits (increase) | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 28,871.43%2.01M |
| Sale of fixed assets | ---- | ---- | ---- | ---- | ---- | -81.79%116K | ---- | -15.63%637K | --769K | -95.23%755K |
| Purchase of fixed assets | ---- | ---- | ---- | ---- | ---- | 77.87%-137K | ---12K | 79.74%-619K | ---- | 78.29%-3.06M |
| Sale of subsidiaries | ---- | ---- | ---- | -100.05%-10K | ---- | 929.28%19.8M | ---- | -347.00%-2.39M | ---- | ---534K |
| Other items in the investment business | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --14K | --14K | ---- |
| Net cash from investment operations | ---- | ---- | ---- | -100.03%-5K | ---- | 940.08%19.78M | -101.53%-12K | -194.74%-2.36M | --783K | -104.03%-799K |
| Net cash before financing | -88.24%14K | 105.42%267K | 104.52%119K | -278.18%-4.93M | 63.75%-2.64M | 111.04%2.76M | 22.46%-7.27M | 73.72%-25.03M | 92.45%-9.37M | -757.27%-95.23M |
| Cash flow from financing activities | ||||||||||
| New borrowing | ---- | ---- | ---- | ---- | ---- | ---- | --7.75M | -91.33%15.6M | ---- | --179.85M |
| Refund | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---81.03M |
| Interest paid - financing | ---- | 79.73%-15K | ---- | 51.95%-74K | ---- | 48.67%-154K | ---- | 64.83%-300K | ---- | 50.58%-853K |
| Net cash from financing operations | ---- | 43.66%-858K | 26.15%-644K | 23.81%-1.52M | -112.93%-872K | -144.97%-2M | 196.14%6.75M | -94.72%4.45M | -104.59%-7.02M | 605.70%84.15M |
| Effect of rate | -143.75%-7K | 63.01%-81K | -91.40%16K | 97.73%-219K | 187.74%186K | -696.60%-9.66M | 89.12%-212K | -95.70%1.62M | -127.42%-1.95M | 508.68%37.62M |
| Net Cash | 102.67%14K | 90.83%-591K | 85.03%-525K | -942.88%-6.45M | -571.84%-3.51M | 103.72%765K | 96.82%-522K | -85.67%-20.58M | -157.44%-16.39M | 60.05%-11.09M |
| Begining period cash | -76.89%202K | -88.41%874K | -88.41%874K | -54.12%7.54M | -54.12%7.54M | -53.57%16.44M | -53.57%16.44M | 299.53%35.4M | 299.53%35.4M | -80.66%8.86M |
| Cash at the end | -42.74%209K | -76.89%202K | -91.35%365K | -88.41%874K | -73.12%4.22M | -54.12%7.54M | -7.96%15.7M | -53.57%16.44M | -53.31%17.06M | 299.53%35.4M |
| Cash balance analysis | ||||||||||
| Currency Unit | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD |
| Accounting Standards | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.